Lilly Claims Proof Of Concept For Neutralizing Antibodies In COVID-19 Therapy

 
• By Joseph Haas

Analysts called the interim data from a Phase II study of LY-CoV555 mixed, but Lilly insists that it has demonstrated a therapeutic role for neutralizing antibodies in fighting the novel coronavirus.

Coronavirus 2019-nCoV Blood Sample. Corona virus outbreaking. Epidemic virus Respiratory Syndrome. China
Lilly is advancing a COVID-19 therapy derived from a patient's blood sample

More from COVID-19

More from Scrip